Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Alkermes plc (ALKS) announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, with management scheduled for a fireside chat presentation on June 9, 2025, at 10:00 a.m. EDT. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia, with operations across Ireland, Massachusetts, and Ohio.
Alkermes plc (ALKS) ha annunciato la sua partecipazione alla 46陋 Conferenza Globale Annuale sulla Sanit脿 di Goldman Sachs, con una presentazione in stile fireside chat prevista per il 9 giugno 2025 alle 10:00 EDT. La presentazione sar脿 disponibile in webcast sul sito web della societ脿 nella sezione Investitori e rester脿 archiviata per 14 giorni. Alkermes 猫 un'azienda biofarmaceutica globale specializzata in neuroscienze, con prodotti commerciali rivolti alla dipendenza da alcol, dipendenza da oppioidi, schizofrenia e disturbo bipolare I. L'azienda dispone di un portafoglio di candidati clinici e preclinici per disturbi neurologici, tra cui narcolessia e ipersonnia idiopatica, con sedi operative in Irlanda, Massachusetts e Ohio.
Alkermes plc (ALKS) anunci贸 su participaci贸n en la 46陋 Conferencia Anual Global de Salud de Goldman Sachs, con una presentaci贸n tipo charla junto a la chimenea programada para el 9 de junio de 2025 a las 10:00 a.m. EDT. La presentaci贸n estar谩 disponible v铆a webcast en el sitio web de la compa帽铆a bajo la pesta帽a de Inversores y permanecer谩 archivada durante 14 d铆as. Alkermes es una empresa biofarmac茅utica global enfocada en neurociencia, con productos comerciales dirigidos a la dependencia del alcohol, dependencia de opioides, esquizofrenia y trastorno bipolar I. La compa帽铆a mantiene una cartera de candidatos cl铆nicos y precl铆nicos para trastornos neurol贸gicos, incluyendo narcolepsia e hipersomnia idiop谩tica, con operaciones en Irlanda, Massachusetts y Ohio.
Alkermes plc (ALKS)電� 2025雲� 6鞗� 9鞚� 鞓れ爠 10鞁�(霃欕秬 響滌鞁�)鞐� 鞓堨爼霅� Goldman Sachs 鞝�46須� 鞐半 旮�搿滊矊 項姢旒�鞏� 旎嵓霟办姢鞐愳劀鞚� 韺岇澊鞏挫偓鞚措摐 毂勴寘 氚滍憸 彀胳棳毳� 氚滍憸頄堨姷雼堧嫟. 氚滍憸電� 須岇偓 鞗轨偓鞚错姼鞚� 韴瀽鞛� 韮棎靹� 鞗轨簮鞀ろ姼搿� 鞁滌箔 臧�電ロ晿氅� 14鞚缄皠 鞎勳勾鞚措笇搿� 氤搓磤霅╇媹雼�. Alkermes電� 鞁犼步瓿柬暀鞐� 欷戩爯鞚� 霊� 旮�搿滊矊 氚旍澊鞓れ牅鞎� 須岇偓搿�, 鞎岇綌鞓� 鞚橃〈歃�, 鞎勴幐鞙犾偓鞝� 鞚橃〈歃�, 臁绊槃氤�, 鞏戧饭靹� 鞛レ暊 I順曥潉 雽�靸侅溂搿� 頃橂姅 靸侅梾鞖� 鞝滍拡鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 旮半┐歃� 氚� 韸闺皽靹� 瓿茧嫟靾橂┐歃濎潉 韽暔頃� 鞁犼步頃欖爜 歆堩櫂鞐� 雽�頃� 鞛勳儊 氚� 鞝勳瀯靸� 頉勲炒氍检 韺岇澊頂勲澕鞚胳潉 鞙犾頃橁碃 鞛堨溂氅�, 鞎勳澕霝滊摐, 毵れ偓於旍劯旄�, 鞓ろ晿鞚挫槫鞐� 鞖挫榿 瓯办爯鞚� 霊愱碃 鞛堨姷雼堧嫟.
Alkermes plc (ALKS) a annonc茅 sa participation 脿 la 46e conf茅rence annuelle mondiale sur la sant茅 de Goldman Sachs, avec une pr茅sentation en format discussion pr茅vue le 9 juin 2025 脿 10h00 EDT. La pr茅sentation sera accessible en webcast sur le site internet de la soci茅t茅 dans la section Investisseurs et restera disponible en archive pendant 14 jours. Alkermes est une entreprise biopharmaceutique mondiale sp茅cialis茅e en neurosciences, avec des produits commerciaux ciblant la d茅pendance 脿 l'alcool, la d茅pendance aux opio茂des, la schizophr茅nie et le trouble bipolaire de type I. L'entreprise dispose d'un portefeuille de candidats cliniques et pr茅cliniques pour les troubles neurologiques, notamment la narcolepsie et l'hypersomnie idiopathique, avec des op茅rations en Irlande, dans le Massachusetts et dans l'Ohio.
Alkermes plc (ALKS) gab seine Teilnahme an der 46. j盲hrlichen globalen Gesundheitskonferenz von Goldman Sachs bekannt, mit einer f眉r den 9. Juni 2025 um 10:00 Uhr EDT geplanten Fireside-Chat-Pr盲sentation des Managements. Die Pr盲sentation wird per Webcast auf der Unternehmenswebsite unter dem Bereich Investoren zug盲nglich sein und f眉r 14 Tage archiviert bleiben. Alkermes ist ein globales biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften und vertreibt kommerzielle Produkte zur Behandlung von Alkoholabh盲ngigkeit, Opioidabh盲ngigkeit, Schizophrenie und bipolarer St枚rung Typ I. Das Unternehmen verf眉gt 眉ber eine Pipeline klinischer und pr盲klinischer Kandidaten f眉r neurologische Erkrankungen wie Narkolepsie und idiopathische Hypersomnie und ist in Irland, Massachusetts und Ohio t盲tig.
Positive
- None.
Negative
- None.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
听
View original content to download multimedia:
SOURCE Alkermes plc
FAQ
When is Alkermes (ALKS) presenting at the Goldman Sachs Healthcare Conference 2025?
Alkermes will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025, at 10:00 a.m. EDT (3:00 p.m. BST).
What products does Alkermes (ALKS) currently have in their portfolio?
Alkermes has commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.
What areas is Alkermes (ALKS) developing new treatments for?
Alkermes is developing clinical and preclinical candidates for neurological disorders, specifically including narcolepsy and idiopathic hypersomnia.
Where are Alkermes' (ALKS) main operational locations?
Alkermes is headquartered in Ireland, with a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
How long will the webcast of Alkermes' (ALKS) presentation be available?
The webcast will be archived and available for 14 days on Alkermes' website under the Investors tab.
Alkermes Plc
NASDAQ:ALKS
ALKS Rankings
ALKS Latest News
ALKS Latest SEC Filings
Sep 8, 2025
[8-K] Alkermes Inc. plc Reports Material Event
Aug 14, 2025
[SCHEDULE 13G/A] Alkermes Inc. plc SEC Filing
Jul 29, 2025
[10-Q] Alkermes Inc. plc Quarterly Earnings Report
ALKS Stock Data
4.77B
161.34M
1.49%
105.04%
8.37%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Ireland
DUBLIN 4